Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Infographic: Scrip 100 Numbers Crunched

Executive Summary

This year's Scrip 100 collection is bigger than ever, encompassing 2016 full-year financial data from more than 650 biopharmaceutical companies.

You may also be interested in...



Scrip 100 Analysis: Impairment, Youth Boost R&D Spending

Spending on R&D increased substantially in 2016; but the picture is complicated and more than half of the increase is due to accountancy updates following drug program failures, one large company's commitment to new projects, and young companies fuelled by generous financial markets.

Bayer's Weinand On Pricing, Payers And Pipelines

Bayer's pharma president and board member Dieter Weinand talks to Scrip about the importance of big picture thinking when weighing the value of innovative drugs to healthcare systems, the revolutionary potential of big data and how "transparency and open dialogue will further enhance the understanding of our business."

Adapt Or Die: Sanofi CSO On R&D Challenges Within Unstable Industry

Sanofi's chief scientific officer Gary Nabel, who joined the company in 2012 from the NIH, discusses R&D challenges for Sanofi and the wider pharma industry, and highlights the company's biggest drug development achievements and toughest moments over the last few years.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC100077

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel